We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
Read MoreHide Full Article
Key Takeaways
ABBV said FDA issued a CRL for TrenibotE's BLA, citing added manufacturing information needs.
FDA flagged no safety or efficacy issues and requested no additional clinical studies.
TrenibotE showed effects as early as 8 hours and lasted 2-3 weeks. Filings are under review globally.
AbbVie (ABBV - Free Report) announced that the FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval of its fast-acting short-duration toxin, trenibotulinumtoxinE (TrenibotE), over manufacturing concerns.
Per the CRL, the FDA has requested additional information regarding the manufacturing processes for TrenibotE and has not identified any concerns related to its safety or efficacy. The regulatory body has not requested any additional clinical studies.
Management believes that it can resolve the FDA’s comments promptly and plans to submit a comprehensive response in the coming months.
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action, with effects observed as early as 8 hours after administration (the earliest assessment time) and a short duration of effect of 2-3 weeks.
Regulatory filings seeking approval for TrenibotE remain under review in other countries worldwide.
Year to date, shares of AbbVie have plunged 12% compared with the industry’s decline of 5.3%.
Image Source: Zacks Investment Research
ABBV’s Struggling Aesthetics Segment
AbbVie is seeing declining sales of its Aesthetics unit due to continued macro challenges and weakened consumer sentiment.
Global sales of ABBV’s aesthetics portfolio declined 5.9% in 2025. Continued macro challenges and low consumer sentiment, especially in the United States, with concerns about the economy and inflation weighing on discretionary spending, are hurting aesthetics sales.
While Juvederm sales declined 15.6% in 2025, Botox Cosmetics sales deteriorated 4.1%. AbbVie expects aesthetics category growth to remain challenged in 2026. Global aesthetics sales are projected to be $5 billion in 2026, flat year over year, as moderate growth in Botox Cosmetic is likely to be offset by continued decline in Juvederm sales due to continued headwinds in key dermal filler markets.
Given the current scenario, the CRL to TrenibotE can be viewed as a major setback for the long-term growth prospects of the Aesthetics segment. An approval for TrenibotE could have improved growth in the segment.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87, while the same for 2027 have increased from $2.85 to $3.25. CPRX shares have gained 18.6% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Agenus’ 2026 earnings per share have risen from 54 cents to $1.30, while loss per share estimates for 2027 have narrowed from $1.91 to $1.52 during the same time. AGEN shares have soared 19.7% year to date.
Agenus’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 31.42%.
Over the past 60 days, Amarin's loss per share estimates for 2026 have narrowed from $7.32 to $6.36, while the same for 2027 have narrowed from $5.97 to $4.64 during the same time. AMRN stock has risen 4.5% year to date.
Amarin's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 51.29%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Shutterstock
AbbVie's TrenibotE Receives FDA CRL Due to Manufacturing Issues
Key Takeaways
AbbVie (ABBV - Free Report) announced that the FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking approval of its fast-acting short-duration toxin, trenibotulinumtoxinE (TrenibotE), over manufacturing concerns.
Per the CRL, the FDA has requested additional information regarding the manufacturing processes for TrenibotE and has not identified any concerns related to its safety or efficacy. The regulatory body has not requested any additional clinical studies.
Management believes that it can resolve the FDA’s comments promptly and plans to submit a comprehensive response in the coming months.
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action, with effects observed as early as 8 hours after administration (the earliest assessment time) and a short duration of effect of 2-3 weeks.
Regulatory filings seeking approval for TrenibotE remain under review in other countries worldwide.
Year to date, shares of AbbVie have plunged 12% compared with the industry’s decline of 5.3%.
Image Source: Zacks Investment Research
ABBV’s Struggling Aesthetics Segment
AbbVie is seeing declining sales of its Aesthetics unit due to continued macro challenges and weakened consumer sentiment.
Global sales of ABBV’s aesthetics portfolio declined 5.9% in 2025. Continued macro challenges and low consumer sentiment, especially in the United States, with concerns about the economy and inflation weighing on discretionary spending, are hurting aesthetics sales.
While Juvederm sales declined 15.6% in 2025, Botox Cosmetics sales deteriorated 4.1%. AbbVie expects aesthetics category growth to remain challenged in 2026. Global aesthetics sales are projected to be $5 billion in 2026, flat year over year, as moderate growth in Botox Cosmetic is likely to be offset by continued decline in Juvederm sales due to continued headwinds in key dermal filler markets.
Given the current scenario, the CRL to TrenibotE can be viewed as a major setback for the long-term growth prospects of the Aesthetics segment. An approval for TrenibotE could have improved growth in the segment.
ABBV's Zacks Rank & Stocks to Consider
AbbVie currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , Agenus (AGEN - Free Report) and Amarin (AMRN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) presently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87, while the same for 2027 have increased from $2.85 to $3.25. CPRX shares have gained 18.6% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Agenus’ 2026 earnings per share have risen from 54 cents to $1.30, while loss per share estimates for 2027 have narrowed from $1.91 to $1.52 during the same time. AGEN shares have soared 19.7% year to date.
Agenus’ earnings beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions, with the average surprise being 31.42%.
Over the past 60 days, Amarin's loss per share estimates for 2026 have narrowed from $7.32 to $6.36, while the same for 2027 have narrowed from $5.97 to $4.64 during the same time. AMRN stock has risen 4.5% year to date.
Amarin's earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 51.29%.